MET and cholangiocarcinoma: After 1 year, the patient developed progressive disease, to which the emergence of epidermal growth factor receptor amplification may have contributed.<h4>Conclusion</h4>Our study verified the therapeutic value of a c-MET inhibitor in advanced CCA-harboring MET amplification and provides an alternative strategy for patients who are intolerant to chemotherapy.